Please login to order a test.
Pain Management Profile (13 Drugs), Urine (PMP-13)
- Immunoassay 13 (Reflexes to GC/MS With Additional Charge)
- LabCorp MedWatch® Monitor Profile
Amphetamine; barbiturate; benzodiazepines; cannabinoid (THC); cocaine; creatinine, urine; fentanyl; meperidine; methadone screen, urine; opiates; oxycodone/oxymorphone, urine; phencyclidine (PCP); pH, urine; propoxyphene; specific gravity; tramadol
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
Initial testing by immunoassay (IA); confirmation of positives by mass spectrometry (MS)
Maintain specimen at room temperature. If arrival at lab extends beyond seven days, then refrigerate.
This panel is designed for pain management. It is not intended for workplace testing and does not comply with state regulatory workplace testing programs. Note: Contains expanded benzodiazepine confirmation upon reflex of positive screen. Opiate confirmation of positive screen includes hydrocodone, hydromorphone, codeine, and morphine.